TAKE16.78

TAKE Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersVIMTALABSSUVENMcap ₹248 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations18.116.913.20.00.00.00.00.00.00.054.230.4
Other Income0.11.10.10.00.08.51.70.00.01.55.21.3
Total Income18.217.913.30.00.08.51.70.00.01.559.431.7
Expenses
+ Cost of Materials Consumed6.06.04.20.00.00.00.00.00.00.00.00.0
+ Purchases of Stock-in-Trade0.00.00.00.00.00.00.00.00.00.054.230.3
+ Employee Benefit Expense3.83.53.50.30.20.40.10.10.10.10.00.1
+ Finance Costs1.41.31.20.50.50.70.20.20.20.00.00.0
+ Depreciation & Amortisation2.21.91.60.00.00.00.00.00.00.00.00.0
+ Other Expenses6.56.220.71.91.02.51.00.60.20.20.80.3
Total Expenses19.818.931.22.71.73.61.41.00.50.455.030.6
EBITDA1.81.1-15.2-2.2-1.2-2.9-1.1-0.8-0.3-0.3-0.8-0.3
EBIT-0.4-0.7-16.8-2.2-1.2-2.9-1.1-0.8-0.3-0.4-0.8-0.3
Profit
PBT before Exceptional Items-1.6-1.0-17.9-2.7-1.74.90.3-0.9-0.51.14.41.1
+ Exceptional Items0.00.0-92.80.00.00.00.00.00.00.00.00.0
Pretax Income-1.6-1.0-110.8-2.7-1.74.90.3-0.9-0.51.14.41.1
+ Current Tax0.00.9-0.40.1-0.10.00.00.00.20.00.00.0
+ Deferred Tax-0.10.30.20.00.00.00.00.00.00.00.00.0
Tax Expense-0.11.2-0.10.1-0.10.00.00.00.20.00.00.0
Net Income-1.5-2.1-110.6-3.7-1.647.7-4.9-0.96.31.14.41.1
+ Net Income — Continuing Ops-1.5-2.1-110.6-2.8-1.74.90.3-0.9-0.61.14.41.1
+ Net Income — Discontinued Ops0.00.00.0-1.00.142.8-5.20.06.90.00.00.0
+ Other Comprehensive Income-0.1-0.00.2-0.00.1-0.10.0-0.00.10.00.00.0
Total Comprehensive Income-1.6-2.1-110.4-3.8-1.547.5-4.8-0.96.31.14.41.1
Net Income to Common-1.5-2.1-110.6-3.7-1.647.7-4.9-0.96.30.0
Per Share
Basic EPS-0.11-0.15-7.56-0.26-0.113.26-0.33-0.060.430.070.290.07
Diluted EPS-0.11-0.15-7.56-0.26-0.113.26-0.33-0.060.430.070.290.07
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax0.00.00.0-1.00.142.8-5.20.06.90.00.00.0
+ Tax — Discontinued Operations0.00.00.00.0-0.00.00.00.00.00.00.00.0
Other Comprehensive Income — detail
+ Other Comprehensive Income0.0-0.00.10.00.0
+ Items NOT to be Reclassified to P&L-0.1-0.00.2-0.00.1-0.00.00.0
+ Tax on Items NOT to be Reclassified — alt tag-0.0-0.00.10.00.00.0
+ Items to be Reclassified to P&L-0.0-0.00.00.0-0.0-0.10.0-0.00.1
Comprehensive Income — Owners of Parent-0.1-0.00.2-3.80.047.50.0-0.90.10.0
Comprehensive Income — Non-controlling Interests0.00.0-110.40.0-1.50.00.00.06.30.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-0.11-0.15-7.56-0.19-0.110.330.02-0.06-0.040.070.290.07
Diluted EPS — Continuing Operations-0.11-0.15-7.56-0.19-0.110.330.02-0.06-0.040.070.290.07
Basic EPS — Discontinued Operations0.000.000.00-0.070.002.93-0.350.000.470.000.000.00
Diluted EPS — Discontinued Operations0.000.000.00-0.070.002.93-0.350.000.470.000.000.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit12.110.99.00.00.00.00.00.00.00.0-0.00.1
Gross Margin %66.8364.4067.87-0.030.35
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-1.6-1.0-17.9-2.7-1.74.90.3-0.9-0.51.14.41.1
− Exceptional Items (reconciliation)0.00.0-92.80.00.00.00.00.00.00.00.00.0
Net Income Adj (tax-effected)-1.5-2.1-17.9-3.7-1.647.7-4.9-0.96.31.14.41.1
EPS Adj-0.11-0.15-1.22-0.26-0.113.26-0.33-0.060.430.070.290.07
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.001.001.001.001.001.001.001.001.00
Paid Up Equity Capital14.614.614.614.614.614.614.614.614.614.814.814.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.